Kornimate/medical-research-clean huggingface dataset:
the protective effect of prostaglandin on coronary microcirculation and ventricular remodeling after reperfusion therapy in acute st-segment elevation myocardial infarction

Conditions: STEMI

Summary: to explore the protective effect of prostaglandin sodium on coronary microcirculation function and ventricular remodeling after reperfusion treatment of acute st-segment elevation myocardial infarction.


Eligibility criteria:
inclusion criteria: * 1) meet the diagnostic criteria for acute st-segment elevation myocardial infarction: ①the onset of ischemic chest pain lasts for more than 30 minutes and cannot be relieved by taking nitroglycerin; ②the ecg has two or more st-segment elevations in adjacent leads , limb leads ≥ 1mm, pectoral leads ≥ 2mm; or newly-appearing left bundle branch block; ③the increase in serum markers of myocardial necrosis is at least twice the normal value; (2) coronary angiography confirmed acute myocardial infarction; (3) direct pci treatment within 12 hours of onset; (4) complete clinical and radiographic data. exclusion criteria: * (1) those who do not cooperate in the inspection, have poor compliance, and cannot guarantee the completion of the test; (2) persons with consciousness impairment, obvious intellectual impairment and mental abnormality; (3) with metal foreign bodies, such as metal prostheses, intraocular metal foreign bodies, intracranial aneurysm clamps, etc.; (4) those who suffer from closure phobia; (5) those who have had a history of myocardial infarction, pci treatment, or coronary artery bypass graft; (6) factors affecting the changes in the st segment of the electrocardiogram: complete left bundle branch block, pre-excitation syndrome, pacemaker electrocardiogram

Keywords: beprostaglandin sodium
evaluation of a screening strategy for sarcopenia: a monocentric prospective cohort study (stras)

Conditions: Sarcopenia

Summary: the main objective of this study is to determine the prevalence of sarcopenia in patients hospitalized in the follow-up care and rehabilitation units of the geriatrics department of the mulhouse french hospital.

secondary objectives 1. to assess the performance of the sarc-f questionnaire to screen for sarcopenia ; 2. to describe the characteristics of sarcopenic patients hospitalized in each follow-up care and rehabilitation unit (i.e. day hospital, full hospitalization); 3. to identify predictive factors of sarcopenia; 4. to determine, in the subgroup of patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), the evolution of sarcopenia between admission and discharge of the following variables : 1. muscle strength, 2. muscle mass, 3. functional ability, 4. dependency. conduct of research after receiving the written consent of the study participant, all of the following tests and questionnaires will be performed : * sarc-f questionnaire, * measurement of muscle strengh by a grip test, * measurement of muscle mass by impedancemetry (asm/size2), * 4-meter walking speed test, * timed-up and go (tug) test, * adl (activities of daily living) and iadl (instrumental activities of daily living) questionnaires. for patients in day hospital care, the study will end upon completion of these tests. for patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), a follow-up visit will be scheduled within 72 hours prior to the patient's discharge from the service, or at 3 months of hospitalization. the following tests and questionnaires will be performed during this visit: * measurement of muscle strengh by a grip test, * measurement of muscle mass by impedancemetry, * 4-meter walking speed test, * timed up and go (tug) test, * adl and iadl questionnaires.

Eligibility criteria:
inclusion criteria: * patient 60 years of age or older * patients hospitalized in the follow-up care and rehabilitation units (i.e. day hospital, full hospitalization) of the geriatrics department of the mulhouse french hospital * patient who gave consent to participate in the study * affiliated or beneficiary of a social security scheme exclusion criteria: * patient admitted for palliative care * bedridden patient * patient with major neurocognitive disorders preventing impedancemetry or grip test from being performed, or any other medical condition preventing impedancemtery or grip test from being performed * patient under legal protection * patient with an unstable psychiatric disorder * patient under guardianship or curatorship * patient already included in the study during a previous hospitalization secondary exclusion criteria : - for patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), impedancemtry or grip test not performed within 7 days of admission. patients excluded secondarily will not be replaced.

Keywords: sarcopenia muscle strength muscle mass older people
hearables: ear-ecg and ppg for detection of cardiac arrhythmias

Conditions: Arrhythmia

Summary: the goal of this observational study is to determine the feasibility of detecting abnormal heart rhythms, known as arrhythmias, by recording electrocardiogram (ecg) and photoplethysmogram (ppg) waveforms from the ears in patients who have already been diagnosed with arrhythmias. the main questions it aims to answer are: * can ecg and ppg signals from the ears reliably detect arrhythmias? * how do ear-based ecg/ppg waveforms compare to standard single-lead ecg in detecting abnormal rhythms? researchers will compare data from healthy controls and arrhythmia patients to see if ear-based recordings are as effective as traditional methods.

the main goal of this study is to determine the feasibility of detecting abnormal heart rhythms, known as arrhythmias, by recording electrocardiogram (ecg) and photoplethysmogram (ppg) waveforms from the ears. the study includes both healthy control subjects and patients who have already been diagnosed with arrhythmias. these individuals will be approached by a clinical member of the research team during their hospital stay or outpatient visit at imperial college nhs trust (ichnt). patients will be given comprehensive information about the study through a patient information sheet and will be asked for their written informed consent, with adequate time provided for questions and understanding. to capture ear-ecg/ppg waveforms, a variety of standard medical-grade sensors and electrodes will be placed in and around both ears. these include standard eeg electrodes on each mastoid secured with medical-grade gel, and an in-ear foam-based earpiece (like commercial earplugs) with cloth electrodes. an additional ppg sensor (max30101 from maxim integrated) will be attached to the back of the ear with adhesive medical tape. the patient will also be connected to a standard single-lead ecg and a blood pressure cuff, already part of their standard care on the hospital ward. once the setup is complete, each patient will follow 3 different recording protocols displayed on a screen. patients will be asked to sit upright (protocol 1) and engage in a series of simple activities with designated breaks in between, including head movements, counting aloud to 60, chewing gum (or simulating chewing), walking (if able) freely under medical supervision with assistance if needed (protocol 2), slow controlled breathing and immersing their hand in cold water (protocol 3). the total recording time including setup will be approximately 20 minutes.

Eligibility criteria:
inclusion criteria: * able to give informed consent; * healthy and diagnosed with cardiac arrhythmias. exclusion criteria: * no abnormal ear anatomy
metabolic abnormalities in hiv-infected persons

Conditions: Lipodystrophy; HIV Infection

Summary: the purpose of this study is to examine the relationship between insulin resistance and changes in body fat distribution in hiv-infected persons. this study measures insulin sensitivity, abdominal fat, and intramuscular fat in hiv-infected persons and examines the effect of an anti-diabetic drug (metformin or pioglitazone) on insulin sensitivity and body fat in this population.

although hiv antiretroviral medications have helped patients live longer, they have also been associated with side effects including insulin resistance and changes in body fat distribution. changes in body fat distribution associated with hiv antiretroviral medications may result in increased fat in the abdomen, neck, and upper back, which is often called central fat deposition. hiv antiretroviral medications may also result in loss of fat in legs, arms, and face, which is often called peripheral fat atrophy. this study will obtain preliminary data on the effect of 12 weeks of metformin on insulin sensitivity and hepatic and peripheral muscle fat in hiv-infected persons with insulin resistance and central fat deposition. similarly, this study will obtain preliminary data on the effect of 12 weeks of pioglitazone on insulin sensitivity and hepatic and peripheral muscle fat in hiv-infected persons with insulin resistance and peripheral fat atrophy. this study involves taking a drug that has been approved by the u.s. food and drug administration (fda) for use in humans for a period of 3 months.

Eligibility criteria:
inclusion criteria: * age 18-70 years * fasting insulin \>12 μu/ml and/or serum glucose between 140-200 mg/dl after 75 g 2hr oral glucose tolerance test * central fat deposition or peripheral fat atrophy * fasting glucose ≤126 mg/dl * bmi ≥18 and ≤35 kg/m2 * cd4 cell count ≥100 cells/mm3 * stable antiretroviral regimen ≥12 weeks and hiv rna \<1000 copies exclusion criteria: * diabetes mellitus * cardiac pacemaker or metal implant * liver enzymes \>2.5x upper normal limit * alkaline phosphatase or prothrombin time \>2x upper normal limit * serum creatinine \>1.4 mg/dl * history of congestive heart failure * hemoglobin \<8 g/dl * alcohol abuse * pregnancy * history of lactic acidosis * use of steroids * acute infection within last one month * history of bladder cancer

Keywords: lipodystrophy insulin resistance hiv infection
effect of roflumilast at acute exacerbations of chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation

Summary: the purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of chronic obstructive pulmonary disease (copd). in addition, the potential benefit of roflumilast on severity and recovery periods of acute copd exacerbations will be assessed using patient diaries and questionnaires.

participants will be asked whether they agree to participate in the measurements of arterial stiffness. participants who agree will be included in the substudy, with the target of 60 patients with arterial stiffness measurements to complete the trial. study was terminated due to difficulty in identifying further eligible patients for this exploratory study within a reasonable time.

Eligibility criteria:
inclusion criteria: * written informed consent (ic) * age ≥ 40 years * history of copd for at least 12 months prior to enrollment (visit v0) * chronic productive cough for 3 months in each of the 2 years prior to enrollment (if other causes of productive cough have been excluded) and/or an exacerbation with predominantly bronchitic symptoms at enrollment * presentation of an acute exacerbation of copd that will be associated with increased sputum volume or change in sputum colour * documented fixed airway obstruction determined by an fev1/fvc ratio (post-bronchodilator) \< 70% (if a pulmonary function test is not possible at visit v0 a previous measurement can be taken which must not be older than 6 months) * former smoker (defined as: smoking cessation at least 1 year ago) or current smoker both with a smoking history of at least 10 pack years main exclusion criteria: * diagnosis of asthma and/or other relevant lung disease * known alpha-1-antitrypsin deficiency * recurrent exacerbations (within 8 weeks of a preceding exacerbation) * treatment of current exacerbation with oral corticosteroids and/or antibiotics already started at enrollment * treatment with pde4 inhibitors within 3 months prior to visit v0 * other protocol-defined exclusion criteria may apply

Keywords: copd chronic obstructive pulmonary disease roflumilast
inter-observer variation in gross tumor delineation of esophageal cancer on mr, ct and pet ct

Conditions: Esophageal Cancer

Summary: the aim of the study is to investigate inter-observer variation in gross tumor volume (gtv) delineation of oesophageal cancer on different imaging modalities - ct, pet ct and mr.twenty-three consecutive patients with esophageal cancer treated with preoperative or curative chemoradiotherapy were selected. all patients had ct, pet ct and mr imaging in treatment position prior to radiotherapy.five experienced observers from our institution will independently delineate gtv on ct alone, mr alone, pet ct alone, on co-registered ct and mr and co-registered pet ct and mr. inter-observer agreement, expressed in generalized conformity index (cigen) and mean volumes of gtv will be calculated per patient and imaging modality.


Eligibility criteria:
inclusion criteria: * locally advanced esophageal cancer eligible for treatment with preoperative or curative chemoradiotherapy exclusion criteria: * contraindications for mr
an open-label extension for the phase 2 study in early symptomatic amyotrophic lateral sclerosis patients on stable background therapy to assess bioenergetic catalysis with cnm-au8 to slow disease progression in als

Conditions: Amyotrophic Lateral Sclerosis

Summary: this is an optional open-label extension to participants that have completed the clinical trial cnmau8.205.

a forty-eight (48) week optional open-label extension period (open- label period), which may be extended by 12-week increments until discontinued by the sponsor for participants that have completed protocol cnmau8.205.

Eligibility criteria:
inclusion criteria: 1. participants must have completed the randomized placebo-controlled treatment period without compliance issues. 2. able to understand and give written informed consent to participate in the open-label extension. 3. if referred from a third party (neurologist or a state based als organisation), participant agrees to maintain transfer of care to a neurologist participating in the study. exclusion criteria: 1. lack of treatment compliance during the randomized placebo controlled treatment period. 2. positive pregnancy test at the week 36 visit, or, females who plan to get pregnant during the course of this extension or within 6 months of the end of this extension. 3. based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or any study procedures. 4. patient with clinically significant abnormalities in haematology, blood chemistry, ecg, or physical examination identified during the w36 visit which according to investigator may interfere with continued participation. 5. patients with clinically significant hepatic or renal dysfunction or clinical laboratory findings that would limit the interpretability of change in liver or kidney function, or those with low platelet counts (\< 150 x 10\^9 per liter) or eosinophilia (absolute eosinophil count of ≥ 500 eosinophils per microliter) at the week 36 visit. 6. patient is considered a suicide risk in the opinion of the investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the investigator.

Keywords: als open-label extension
clinical outcomes of patients with lal+ in at least one eye

Conditions: IOL, Cataract

Summary: the objective of this study is to collect data on bilateral pseudophakic patients implanted with the rxsight light adjustable lens+ (lal+) in at least one eye

a retrospective-prospective, single-center study will be conducted. patient charts will be retrospectively reviewed to collect data from the patient's comprehensive preoperative exam. subjects will attend one stud visit post final ldd light treatment.

Eligibility criteria:
inclusion criteria: * adults with bilateral pseudophakia who have been implanted with the lal+ in at least one eye and who have completed ldd light treatments * sign a written informed consent form exclusion criteria: * visually significant eye disease

Keywords: lal+ light adjustable lens+ mix and match iols
the effect of adding instrumented hip concentric abductor strengthening exercise in knee osteoarthritis

Conditions: Knee Osteoarthritis; Pain; Physical Disability

Summary: the aim of this study was to investigate the effectiveness of adding hip device-assisted concentric abductor strengthening (hdacas) program to knee device-assisted concentric flexor-extensor strengthening (kdacfes) program on pain, function, physical performance, quality of life and gait parameters in patients with knee osteoarthritis (oa).

this prospective randomized single-blind controlled study was conducted at kütahya health sciences university (khsu) evliya çelebi education and research hospital (ecerh) physical medicine and rehabilitation (pmr) annex building between september 2023 and march 2024. the study protocol was approved by the ethics committee of the same university (2023-03/03).

Eligibility criteria:
inclusion criteria: * receiving a diagnosis of knee osteoarthritis according to the acr criteria and being classified as stage 2-3 according to the kellgren lawrence staging * having symptomatic unilateral or bilateral knee pain with a vas (0-10) pain score \> 4 * being able to ambulate independently without orthosis/prosthesis * having a body mass index less than 35 exclusion criteria: * history of knee and hip surgery * presence of lesions, atrophy, or scars in the skin area * intra-articular injection to the knee within the last 6 months * receiving active physiotherapy, physical therapy, or spa treatment in the last 6 months * patients with chronic diseases such as copd, coronary artery disease * those with oxygen saturation levels \<95% * individuals with any pathological condition that may impair normal walking * patients with diseases such as vertigo, epilepsy that may pose a risk during physical performance tests * patients with contraindications to strength training exercises
phase 1 study of mln0264 in adult patients with advanced gastrointestinal malignancies expressing guanylyl cyclase c

Conditions: Advanced Gastrointestinal Malignancies

Summary: this is an open-label, multicenter, dose escalation, first-in-human study of mln0264 in adult patients with advanced gastrointestinal malignancies expressing guanylyl cyclase c.


Eligibility criteria:
inclusion criteria: * voluntary consent form * diagnosis of gi malignancy with a gcc protein expressing tumor * male or female patients 18 years or older with measurable disease as defined by response evaluation criteria in solid tumors (recist) * female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse * male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate bone marrow, hepatic and renal function as specified in the protocol exclusion criteria: * female patients who are lactating or have a positive serum pregnancy test during the screening period * any serious medical or psychiatric illness that could interfere with the completion of treatment * major surgery or treatment with investigational drug before the first dose * serious infection within 14 days before the first dose of study drug * known hiv, inflammatory bowel disease, viral hepatitis or cerebral/meningeal brain metastases * patients with cardiovascular conditions specified in protocols * patients with history of another primary malignancy not in remission for at least 3 years please note that there are additional inclusion and exclusion criteria. the study center will determine if you meet all of the criteria. site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. you can then decide whether or not you wish to participate. if you do not qualify for the trial, site personnel will explain the reasons.

Keywords: phase 1, advanced gastrointestinal malignancies, mln0264, guanylyl cyclase c(gcc), antibody drug conjugate(adc)
long term outcome of extracorporeal membrane oxygenation patients in china

Conditions: Long-term Outcome; Extracorporeal Membrane Oxygenation

Summary: outcomes and long-term quality-of-life of patients requiring extracorporeal membrane oxygenation are not known in china. a prospective study survey will be performed to assess the long-term outcome of these patients.

patients admitted to icus and treated with extracorporeal membrane oxygenation from march 1,2015 to march 1,2019 were screened . pre-ecmo clinical parameters(diagnose,apache-ii, sofa,indications,expected mortality) and related treatment conditions(duration of icu stay, duration of ecmo,duration of mechanical ventilation,ventilation conditions,prone ventilation,ecmo complications )will be used to assess the severity and curative effect of these patients.short form-36 health status questionnaire,euroqol-5 dimensions and st. george's respiratory questionnaire(sgrq) will deliver in these survivors ,which are used to assess the physical and mental health ,as well as the social adaptation. finally a comprehensive assessment will be obtained to describe the outcomes and long-term quality-of-life of patients treated with ecmo.

Eligibility criteria:
inclusion criteria: * require extracorporeal membrane oxygenation exclusion criteria: * irreversible disease

Keywords: respiratory failure, circulatory failure
a study of telemedicine shared medical appointments (smas) versus individual telemedicine visits for people with prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to see if a telemedicine group doctor's appointment is a practical (feasible) and acceptable method for following people with prostate cancer being managed with active surveillance when compared with the usual approach of individual telemedicine visits, which involve the participant visiting a doctor on their own. the researchers will compare the telemedicine group and individual visits by measuring on participant satisfaction and quality of life in each type of visit. telemedicine is the use of secure video technology on a desktop computer, laptop, smartphone, or tablet to provide and receive healthcare from a distance.


Eligibility criteria:
inclusion criteria: * a scheduled appointment for a subsequent active surveillance (as) follow-up visit for management of localized prostate cancer * biopsy gleason score 3+3=6 (grade group 1) or biopsy gleason score 3+4=7 (grade group 2) * clinical t stage ≤t2b * access to a device with zoom * ability to speak and understand english exclusion criteria: * plan to undergo a prostate biopsy at this follow-up visit

Keywords: telemedicine shared medical appointments individual telemedicine visits 22-184